SynthesisClinical pharmacology and therapeutics2019
Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.
Open access · hybridAbstract readMeta-Analysis
In one paragraph
Synthesis in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review.BioMed research international · 2019Pooled it
- Pivotal Factors for Minimizing the Risks of Therapeutic Failure in Trigeminal Neuralgia and Hemifacial Spasm.Current pain and headache reports · 2026Review
- A multi-ancestry genetic reference for the Quebec population.Nature communications · 2026Article
- Human Leukocyte Antigen (International journal of molecular sciences · 2026Review
- RUCAM-ascertained immunology and autoimmunity specifics of six idiosyncratic drug-induced liver injury types with refined classification: their individual complex molecular interplay.Frontiers in immunology · 2026Review
- Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity.International journal of molecular sciences · 2025Review
- Drug hypersensitivity reactions in children in clinical practice: A WAO Statement.The World Allergy Organization journal · 2025Review
- Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology.Allergy · 2025Review
- Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population.Biomarker research · 2024Article
- Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method.Medicines (Basel, Switzerland) · 2024Review
- Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet.Pharmacological research · 2024Article
- Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications.The pharmacogenomics journal · 2023Article
- [Genetic susceptibility to drug-induced liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Pharmacogenomics: current status and future perspectives.Nature reviews. Genetics · 2023Review
- Characterization of Drug-Specific CD4Chemical research in toxicology · 2023Article
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses.Microorganisms · 2023Review
- Updates in SJS/TEN: collaboration, innovation, and community.Frontiers in medicine · 2023Review
- Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity.The journal of allergy and clinical immunology. In practice · 2022Article
- Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.Acta pharmaceutica Sinica. B · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 19 institutions in 9 countries.
Paola NicolettiIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Sarah BarrettDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Laurence McEvoyDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.ORCID 0000-0002-2169-6735
Ann K DalyInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-7321-0629
Guruprasad AithalNational Institute for Health Research (NIHR) Nottingham Biomedical Research Unit, Center at the Nottingham University Hospital NHS Trust and University of Nottingham, Nottingham, UK.
M Isabel LucenaUGC Digestivo, Clinical Pharmacology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.ORCID 0000-0001-9586-4896
Raul J AndradeUGC Digestivo, Clinical Pharmacology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.ORCID 0000-0002-1565-0757
Mia WadeliusDepartment of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-6368-2622
Pär HallbergDepartment of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-3465-3280
Camilla StephensUGC Digestivo, Clinical Pharmacology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Einar S BjornssonDepartment of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland.
Peter FriedmannDermatology Unit, School of Medicine, University of Southampton, Southampton, UK.
Kati KainuClinical Research Unit for Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, Finland.
Tarja LaitinenClinical Research Unit for Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, Finland.
Anthony MarsonDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Mariam MolokhiaSchool of Population Sciences and Health Services Research, King's College, London, UK.
Elizabeth PhillipsDepartiment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Werner PichlerADR-AC GmbH, Bern, Switzerland.
Antonino RomanoAllergy Unit, Complesso Integrato Columbus, Rome, Italy.
Neil ShearSunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-9151-1145
Graeme SillsDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Luciana K TannoHospital Sírio Libanês, São Paulo, Brazil.
Ashley SwaleDepartment of Systems Biology, Columbia University, New York, New York, USA.ORCID 0000-0002-2985-5059
Aris FloratosDepartment of Systems Biology, Columbia University, New York, New York, USA.
Yufeng ShenDepartment of Systems Biology, Columbia University, New York, New York, USA.
Matthew R NelsonTarget Sciences, GSK, King of Prussia, Pennsylvania, USA.
Paul B WatkinsEshelman School of Pharmacy, University of North Carolina Institute for Drug Safety Sciences, Chapel Hill, North Carolina, USA.
Mark J DalyAnalytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Andrew P MorrisDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Ana AlfirevicDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Munir PirmohamedDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.ORCID 0000-0002-7534-7266
University of Liverpool · GBCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESColumbia University · USHelsinki University Hospital · FIUppsala University · SEADR-AC (Switzerland) · CHENT and Allergy · USHarvard University · USHospital Sírio-Libanês · BRKing's College London · GBNewcastle University · GBReykjavík University · ISSema4 (United States) · USSunnybrook Health Science Centre · CATarget (United States) · USUniversity of North Carolina at Chapel Hill · USUniversity of Nottingham · GBUniversity of Southampton · GBVanderbilt University Medical Center · US
Funding
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2015 to 2019
$13.0MSingle Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysisR21AI139021 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2019
$435kNATIENS: A Phase III Randomized Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisR34AI136815 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2018
$205kDepartment of Health 09/144/09Department of Health RP-PG-0606-1062Medical Research Council G0800637Medical Research Council MR/L006758/1Medical Research Council MR/N005953/1NIAID NIH HHS R21 AI139021NIAID NIH HHS R34 AI136815NIGMS NIH HHS P50 GM115305Wellcome Trust WT098017
Abstract
Carbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI). In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-analysis of two genomewide association studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls. HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10
Indexed as
AdultAnaplastic Lymphoma KinaseCarbamazepineChemical and Drug Induced Liver InjuryDrug HypersensitivityDrug Hypersensitivity SyndromeEuropeFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHLA-A AntigensHLA-B AntigensHumansMalePhenotypeRisk FactorsALK protein, humanAnaplastic Lymphoma KinaseCarbamazepineHLA-A AntigensHLA-B Antigens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.